DRUG
LY3437943
Administered subcutaneously (SC)
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
Status
Completed
Phase
Phase 1
Enrollment
45
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3437943 or placebo. The study will last up to approximately 71 days for each participant, including screening.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Feb 15, 2019
Study start
Mar 13, 2019
Primary completion
Jul 25, 2019
Study completion
Jul 25, 2019
Results posted
Not reported
Registry updated
Aug 6, 2019
Outcomes
What the study measures.
Primary outcomes
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame · Baseline through final follow-up at approximately Day 43
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Secondary outcomes
Pharmacokinetics: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3437943
Time frame · Baseline through final follow-up at approximately Day 43
Pharmacokinetics: AUC(0-inf) of LY3437943
Pharmacokinetics: Maximum Concentration (Cmax) of LY3437943
Time frame · Baseline through final follow-up at approximately Day 43
Pharmacokinetics: Cmax of LY3437943
Pharmacokinetics: Time to Maximum Concentration (Tmax) of LY3437943
Time frame · Baseline through final follow-up at approximately Day 43
Pharmacokinetics: Tmax of LY3437943
Eligibility
Who can take part.
- Minimum age
- 21 Years
- Maximum age
- 65 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Overtly healthy male or a female who cannot get pregnant * Have a body mass index (BMI) between 19 and 40 kilograms per square meter (kg/m²), inclusive, at screening * Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study * Have veins suitable for ease of blood sampling Exclusion Criteria: * Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study * Have previously completed or withdrawn from this study * Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking during the inpatient stay in the study * Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study * Have been treated with weight loss medications within 3 months of screening
Study locations
1 registered sites.
Singapore. Showing up to 24 locations stored in the fast local snapshot.
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Retatrutide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.